Find Testosterone Undecanoate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

GLOBAL SALES INFORMATION

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 5949-44-0, Andriol, Testosterone undecylate, Nebido, Testosterone (undecanoate), Aveed
Molecular Formula
C30H48O3
Molecular Weight
456.7  g/mol
InChI Key
UDSFVOAUHKGBEK-CNQKSJKFSA-N
FDA UNII
H16A5VCT9C

Testosterone Undecanoate
Testosterone Undecanoate is the undecanoate ester form of the androgen testosterone, with gonadotropin-secretory inhibiting and hormone replacement activity. As testosterone inhibits the secretion of gonadotropins from the pituitary gland, administration of testosterone decreases the secretion of luteinizing hormone (LH). By inhibiting LH secretion, the growth of Leydig cells, which are normally stimulated by LH to produce testosterone, may be suppressed. In addition, this agent promotes the maintenance of male sex characteristics and can be used for testosterone replacement in hypogonadal males.
1 2D Structure

Testosterone Undecanoate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] undecanoate
2.1.2 InChI
InChI=1S/C30H48O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h21,24-27H,4-20H2,1-3H3/t24-,25-,26-,27-,29-,30-/m0/s1
2.1.3 InChI Key
UDSFVOAUHKGBEK-CNQKSJKFSA-N
2.1.4 Canonical SMILES
CCCCCCCCCCC(=O)OC1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C
2.1.5 Isomeric SMILES
CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
2.2 Other Identifiers
2.2.1 UNII
H16A5VCT9C
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Andriol

2. Nebido

3. Pantestone

4. Restandol

5. Testosterone Undecylate

6. Undestor

2.3.2 Depositor-Supplied Synonyms

1. 5949-44-0

2. Andriol

3. Testosterone Undecylate

4. Nebido

5. Testosterone (undecanoate)

6. Aveed

7. Org 538

8. Testosterone Undeconate

9. Jatenzo

10. Testosterone Undecanoate [usan]

11. Testosterone, Undecanoate (ester)

12. Undestor

13. H16a5vct9c

14. Org-538

15. Testosterone 17.beta.-undecylate

16. Tsx-011

17. [(8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] Undecanoate

18. Mk-3033

19. Androst-4-en-3-one, 17-[(1-oxoundecyl)oxy]-, (17b)-

20. Pantestone

21. Restandol

22. T Undecanoate

23. Testosterone Undecanoate (usan)

24. Rextoro

25. Nebido-r

26. Reandron 1000

27. Einecs 227-712-6

28. Unii-h16a5vct9c

29. Brn 3176734

30. 17beta-hydroxyandrost-4-en-3-one Undecanoate

31. Andriol (tn)

32. Aveed (tn)

33. 5-alpha-androstan-3-one, 17-beta-hydroxy-, Undecanoate

34. Bay 86-5037

35. 3-oxoandrost-4-en-17beta-yl Undecanoate

36. Androst-4-en-3-one, 17-((1-oxoundecyl)oxy)-, (17-beta)-

37. Testosterone, Undecanoate

38. 4-08-00-00981 (beilstein Handbook Reference)

39. Schembl147620

40. Chembl2107067

41. Clr-610

42. Dtxsid90863661

43. Chebi:135741

44. Androst-4-en-3-one, 17-((1-oxoundecyl)oxy)-, (17beta)-

45. (8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl Undecanoate

46. Bcp11921

47. Hy-b0626

48. Zinc8214690

49. Mfcd00468114

50. Testosterone Undecanoate [mi]

51. Akos016010255

52. Cs-4342

53. Db13946

54. Gs-6598

55. Testosterone Undecylate [mart.]

56. 17beta-undecanoyloxy-4-androsten-3-one

57. Testosterone Undecanoate [vandf]

58. Ncgc00484056-01

59. Testosterone Undecanoate [who-dd]

60. Testosterone Undecanoate [orange Book]

61. D06087

62. (17beta)-3-oxoandrost-4-en-17-yl Undecanoate

63. (17-beta)-3-oxoandrost-4-en-17-yl Undecanoate

64. 949t440

65. 3-oxoandrost-4-en-17.beta.-yl Undecanoate

66. W-105318

67. Q15410178

68. 17.beta.-hydroxyandrost-4-en-3-one Undecanoate

69. (17.beta.)-17-hydroxyandrost-4-en-3-one Undecanoate

70. 5-.alpha.-androstan-3-one, 17-.beta.-hydroxy-, Undecanoate

71. Androst-4-en-3-one, 17-[(1-oxoundecyl)oxy]-, (17.beta.)-

72. .delta.(sup 4)-androsten-17.beta.-ol-3-one Undecanoate

73. Androst-4-en-3-one, 17-((1-oxoundecyl)oxy)-(17.beta.)

74. (1s,2r,10r,11s,14s,15s)-2,15-dimethyl-5-oxotetracyclo[8.7.0.0?,?.0??,??]heptadec-6-en-14-yl Undecanoate

75. (1s,2r,10r,11s,14s,15s)-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-14-yl Undecanoate

2.4 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 456.7 g/mol
Molecular Formula C30H48O3
XLogP38.5
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count3
Rotatable Bond Count11
Exact Mass456.36034539 g/mol
Monoisotopic Mass456.36034539 g/mol
Topological Polar Surface Area43.4 Ų
Heavy Atom Count33
Formal Charge0
Complexity739
Isotope Atom Count0
Defined Atom Stereocenter Count6
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameAveed
PubMed HealthTestosterone (Injection)
Drug ClassesEndocrine-Metabolic Agent
Drug LabelAveed (testosterone undecanoate) injection contains testosterone undecanoate (17-undecanoyloxy-4-androsten-3-one) which is an ester of the androgen, testosterone. Testosterone is formed by cleavage of the ester side chain of testosterone undecanoat...
Active IngredientTestosterone undecanoate
Dosage FormInjectable
RouteIntramuscular
Strength750mg/3ml (250mg/ml)
Market StatusPrescription
CompanyEndo Pharms

2 of 2  
Drug NameAveed
PubMed HealthTestosterone (Injection)
Drug ClassesEndocrine-Metabolic Agent
Drug LabelAveed (testosterone undecanoate) injection contains testosterone undecanoate (17-undecanoyloxy-4-androsten-3-one) which is an ester of the androgen, testosterone. Testosterone is formed by cleavage of the ester side chain of testosterone undecanoat...
Active IngredientTestosterone undecanoate
Dosage FormInjectable
RouteIntramuscular
Strength750mg/3ml (250mg/ml)
Market StatusPrescription
CompanyEndo Pharms

4.2 Drug Indication

Testosterone undecanoate is indicated for replacement therapy in adult males with conditions that are linked with an absence or deficiency in endogenous testosterone production.


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Testosterone plays a key role in male sexual differentiation and is involved in regulation of hematopoiesis, body composition, and bone metabolism. As a result, testosterone replacement therapy in males with hypogonadism can result in improved sexual function, increased lean body mass, bone density, erythropoiesis, prostate size, and changes in lipid profiles.


5.2 MeSH Pharmacological Classification

Androgens

Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. (See all compounds classified as Androgens.)


5.3 FDA Pharmacological Classification
5.3.1 Pharmacological Classes
Androgen [EPC]; Androstanes [CS]; Androgen Receptor Agonists [MoA]
5.4 Absorption, Distribution and Excretion

Absorption

The absorption of testosterone undecanoate varies based on the formulation. The intramuscular formulation of testosterone esters is suspended in oil and is absorbed from the lipid phase. Testosterone is released when tissue esterases cleave the undecanoic acid side chain. The oral formulation of testosterone undecanoate is also formulated as a prodrug, is best absorbed with food and ideal absorption occurs when taken with a meal containing at least 30 g of fat.


Route of Elimination

The majority (~90%) of an intramuscularly administered dose of testosterone is conjugated and eliminated in the urine. Approximately 6% of the dose is eliminated primarily unconjugated in the feces.


5.5 Metabolism/Metabolites

The side chain of testosterone undecanoate is cleaved by non specific esterases when it enters circulation and the undecanoic acid side chain is metabolized by the beta-oxidation pathway. The resulting Testosterone molecule is then metabolized to dihydrotestosterone (DHT) by the enzyme 5-alpha reductase. DHT is reduced by 3-alpha-hydroxysteroid dehydrogenase (major) and 3-beta-hydroxysteroid dehydrogenase prior to being glucuronidated and cleared by the kidneys. It should be noted that testosterone is metabolized to several other 17-keto steroids in the body.


5.6 Biological Half-Life

Based on one source, Testosterone undecanoate in castor oil (for intramuscular injection) has a half life of 33.9 days, allowing it to maintain serum levels in the normal range for over 6 weeks. It should be noted that the half life of testosterone reported in the literature is inconsistent.


5.7 Mechanism of Action

Testosterone is produced by Leydig cells and exerts it's effects by binding to androgen receptors throughout the body. Testosterone affects the voice, genitalia, mood, and influences muscle growth and protein expression. Accordingly, males with low levels of testosterone often experience decreased libido, fatigue, mood changes and dysphoria. Exogenous sources of testosterone are designed to mimic the effects of endogenous testosterone.


Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Parenteral

read-more
read-more

Topical

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions
Drug Master Files, or DMFs, are confidential documents that play a crucial role in the pharmaceutical industry. These files, submitted to the US Food and Drug Administration (FDA), contain detailed information about ingredients, manufacturing processes, and packaging of medicines. They help the FDA oversee drug quality. Of the four types, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs. The third quarter (Q3) of 2024 saw Type II DMF submissions set a new record. A total of 309 Type II DMFs were submitted to the FDA during this period, a substantial 24.6 percent increase over Q3 2023 (with 248 submissions). The second quarter of 2024 too saw a remarkable increase, with 237 Type II DMFs being submitted compared to 178 in Q2 2023. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) China witnesses steep rise in DMF submissions, beats India with maximum filings In Q3 2024, China filed 153 DMFs submissions, marking a substantial 57.7 percent increase from the 97 submissions filed in Q3 2023. India maintained its strong position but fell to the number two spot with 110 DMFs, representing a modest 3.8 percent increase from 106 in Q3 2023. The US, which came a distant third, saw a slight decline in DMF submissions, with 13 filed in Q3 2024, as compared to 18 in Q3 2023. For several years, India had a lead in Type II DMFs. Since 2020, which marked the start of the pandemic, we have noticed a gradual increase in DMFs filed by China. This year, China has surpassed India considerably in the first three quarters. During the first nine months of 2024, China submitted 372, while India filed 286 DMFs. If this lead is maintained in Q4, DMFs from China will surpass that of India in 2024.  Amongst European countries, Spain led with seven DMFs, followed by Italy at four, and Germany and the Netherlands at three each. Among other nations, Japan contributed six while Israel submitted four DMFs. In company-wise tally, China’s Jiangsu East-Mab Biomedical Technology topped the list with an impressive 14 DMFs. On its heels were Indian companies — MSN at 13 DMFs, and Vamsi Labs and Hetero Drugs at nine DMFs each. China’s Porton Pharma and Wuxi AppTec filed five, while Shanghai Keze Yongxin Biotechnology, and Qingdao Glycogene Pharmaceutical contributed four submissions each. India's Maithri Drugs also submitted four. Japanese company Santeja filed five. Overall, Asia accounted for nearly 90 percent, with China contributing a dominant 49.5 percent of all DMF submissions. India was at 35.6 percent, the US at 4.2 percent, while Europe contributed 6.5 percent.  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) Diabetes, obesity, cancer, women’s health drugs emerge as hot molecules in Q3 2024 In terms of molecules, semaglutide (used for the treatment of type 2 diabetes and weight management) and relugolix (to treat prostate cancer and uterine fibroids) saw six DMF filings each in Q3 2024, indicating significant industry interest in these compounds. Following closely behind were semaglutide’s competitor tirzepatide and overactive bladder therapy vibegron, garnering four DMFs each. Finerenone (a non-steroidal drug for chronic kidney disease associated with type 2 diabetes) and voclosporin (an immunosuppressant for lupus nephritis) saw three DMFs each.  The last quarter also witnessed the introduction of 14 molecules with first-time DMFs. Among them were acetoxy empagliflozin, cabozantinib fumarate, tivozanib hydrochloride monohydrate, diosmetin, trilaciclib, clenbuterol hydrochloride, fenoterol hydrobromide, tapinarof and fezolinetant. Fezolinetant, with a DMF from Spain’s Moehs Iberica, is the active ingredient in Astellas’ Veozah, which is the first non-hormonal treatment for menopausal symptoms approved by the FDA. Tapinarof, filed by India’s Maithri Drugs, is used in Vtama, a novel steroid-free psoriasis cream. Other compounds that made their DMF debut include berotralstat, calcium phosphoryl choline chloride, phloroglucinol dihydrate, belumosudil mesylate and trimethylphloroglucinol. During Q2 2024, there were 19 drugs that saw DMF submissions for the first time, including molecules like triptorelin, sorafenib, pralsetinib, trilaciclib dihydrochloride, resmetirom (hepatology) and teneligliptin hydrochloride hydrate (metabolic disorders).  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available)    GDUFA fee for FY 2025: The FDA’s Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry. The fiscal year 2025 fee rates were published on July 31, 2024. The FDA has revised fees under GDUFA III for all categories. While there is a slight increase in the DMF fee from US$ 94,682 in 2024 to US$ 95,084 in 2025, the ANDA fee has witnessed a significant jump — from US$ 252,453 in 2024 to US$ 321,920 in 2025. FY 2024 and FY 2025 User Fee Rates Generic drug fee category Fees rates for FY 2024 Fees rates for FY 2025 Applications: Abbreviated New Drug Application (ANDA) US$ 2,52,453   US$ 3,21,920   Drug Master File (DMF) US$ 94,682 US$ 95,084 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 40,464 US$ 41,580 API—Foreign US$ 55,464 US$ 56,580 Finished Dosage Form (FDF)—Domestic US$ 2,20,427   US$ 2,31,952 FDF—Foreign US$ 2,35,427   US$ 2,46,952 Contract Manufacturing Organization (CMO)—Domestic US$ 52,902 US$ 55,668 CMO—Foreign US$ 67,902 US$ 70,668 GDUFA Program: Large size operation generic drug applicant US$ 17,29,629   US$ 18,91,664 Medium size operation generic drug applicant US$ 6,91,852   US$ 7,56,666 Small business generic drug applicant US$ 1,72,963   US$ 1,89,166 Our view The highlight of the last few quarters has been the sharp rise in Type II DMF filings from China. The submission of a DMF is not required by law or any FDA regulation. FDA’s DMF guideline offers guidance on acceptable approaches to meeting regulatory requirements. Moreover, DMFs establish trust in APIs from lesser-known companies. With a growing emphasis on compliance and quality assurance, it appears that Chinese drug companies are eager to demonstrate their commitment to high standards and build trust in the US market. And that’s good news for the pharmaceutical industry.   

Impressions: 10421

https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions

#PharmaFlow by PHARMACOMPASS
24 Oct 2024

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
RDD
Not Confirmed

ENDO OPERATIONS

Ireland
arrow
RDD
Not Confirmed

TESTOSTERONE UNDECANOATE

US Patent Number : 7718640

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 22219

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-03-14

blank

02

arrow
RDD
Not Confirmed

MARIUS

U.S.A
arrow
RDD
Not Confirmed

TESTOSTERONE UNDECANOATE

US Patent Number : 12357643

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213953

Patent Use Code : U-2506

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-03-15

blank

03

arrow
RDD
Not Confirmed

MARIUS

U.S.A
arrow
RDD
Not Confirmed

TESTOSTERONE UNDECANOATE

US Patent Number : 12357643

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213953

Patent Use Code : U-2506

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-03-15

blank

04

arrow
RDD
Not Confirmed

MARIUS

U.S.A
arrow
RDD
Not Confirmed

TESTOSTERONE UNDECANOATE

US Patent Number : 12357643

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213953

Patent Use Code : U-2506

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-03-15

blank

05

arrow
RDD
Not Confirmed

TOLMAR

U.S.A
arrow
RDD
Not Confirmed

TESTOSTERONE UNDECANOATE

US Patent Number : 8492369

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 206089

Patent Use Code : U-2506

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-12-20

blank

06

arrow
RDD
Not Confirmed

TOLMAR

U.S.A
arrow
RDD
Not Confirmed

TESTOSTERONE UNDECANOATE

US Patent Number : 8778916

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 206089

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-04-12

blank

07

arrow
RDD
Not Confirmed

TOLMAR

U.S.A
arrow
RDD
Not Confirmed

TESTOSTERONE UNDECANOATE

US Patent Number : 8778916

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 206089

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-04-12

blank

08

arrow
RDD
Not Confirmed

TOLMAR

U.S.A
arrow
RDD
Not Confirmed

TESTOSTERONE UNDECANOATE

US Patent Number : 10617696

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 206089

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-04-12

blank

09

arrow
RDD
Not Confirmed

TOLMAR

U.S.A
arrow
RDD
Not Confirmed

TESTOSTERONE UNDECANOATE

US Patent Number : 10617696

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 206089

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-04-12

blank

10

arrow
RDD
Not Confirmed

VERITY

Canada
arrow
RDD
Not Confirmed

TESTOSTERONE UNDECANOATE

US Patent Number : 12011503

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 208088

Patent Use Code : U-3965

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2040-10-16

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Looking for 5949-44-0 / Testosterone Undecanoate API manufacturers, exporters & distributors?

Testosterone Undecanoate manufacturers, exporters & distributors 1

32

PharmaCompass offers a list of Testosterone Undecanoate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Testosterone Undecanoate manufacturer or Testosterone Undecanoate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Testosterone Undecanoate manufacturer or Testosterone Undecanoate supplier.

API | Excipient name

Testosterone Undecanoate

Synonyms

5949-44-0, Andriol, Testosterone undecylate, Nebido, Testosterone (undecanoate), Aveed

Cas Number

5949-44-0

Unique Ingredient Identifier (UNII)

H16A5VCT9C

About Testosterone Undecanoate

Testosterone Undecanoate is the undecanoate ester form of the androgen testosterone, with gonadotropin-secretory inhibiting and hormone replacement activity. As testosterone inhibits the secretion of gonadotropins from the pituitary gland, administration of testosterone decreases the secretion of luteinizing hormone (LH). By inhibiting LH secretion, the growth of Leydig cells, which are normally stimulated by LH to produce testosterone, may be suppressed. In addition, this agent promotes the maintenance of male sex characteristics and can be used for testosterone replacement in hypogonadal males.

Nebido Manufacturers

A Nebido manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nebido, including repackagers and relabelers. The FDA regulates Nebido manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nebido API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Nebido manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Nebido Suppliers

A Nebido supplier is an individual or a company that provides Nebido active pharmaceutical ingredient (API) or Nebido finished formulations upon request. The Nebido suppliers may include Nebido API manufacturers, exporters, distributors and traders.

click here to find a list of Nebido suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Nebido USDMF

A Nebido DMF (Drug Master File) is a document detailing the whole manufacturing process of Nebido active pharmaceutical ingredient (API) in detail. Different forms of Nebido DMFs exist exist since differing nations have different regulations, such as Nebido USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Nebido DMF submitted to regulatory agencies in the US is known as a USDMF. Nebido USDMF includes data on Nebido's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nebido USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Nebido suppliers with USDMF on PharmaCompass.

Nebido KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Nebido Drug Master File in Korea (Nebido KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Nebido. The MFDS reviews the Nebido KDMF as part of the drug registration process and uses the information provided in the Nebido KDMF to evaluate the safety and efficacy of the drug.

After submitting a Nebido KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Nebido API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Nebido suppliers with KDMF on PharmaCompass.

Nebido WC

A Nebido written confirmation (Nebido WC) is an official document issued by a regulatory agency to a Nebido manufacturer, verifying that the manufacturing facility of a Nebido active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nebido APIs or Nebido finished pharmaceutical products to another nation, regulatory agencies frequently require a Nebido WC (written confirmation) as part of the regulatory process.

click here to find a list of Nebido suppliers with Written Confirmation (WC) on PharmaCompass.

Nebido NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nebido as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Nebido API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Nebido as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Nebido and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nebido NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Nebido suppliers with NDC on PharmaCompass.

Nebido GMP

Nebido Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Nebido GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Nebido GMP manufacturer or Nebido GMP API supplier for your needs.

Nebido CoA

A Nebido CoA (Certificate of Analysis) is a formal document that attests to Nebido's compliance with Nebido specifications and serves as a tool for batch-level quality control.

Nebido CoA mostly includes findings from lab analyses of a specific batch. For each Nebido CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Nebido may be tested according to a variety of international standards, such as European Pharmacopoeia (Nebido EP), Nebido JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nebido USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty